Cryo Preservation of Human Dendritic Cells for Clinical Use

Чкадуа, Г. З.; Борунова, А А; Шоуа, И. Б.; Долгополов, И. С.; Пименов, Р. И.; Михайлова, И. Н.; Заботина, Т. Н.; Барышникова, М А

doi:10.17650/1726-9784-2019-18-4-65-75

Cited by 3 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Для сбора 2-3×10 9 мононуклеарных клеток было обработано в среднем 0,7 (0,5-1,3) объема циркулирующей крови пациента. Стандартная методика подготовки ДВ и криоконсервации была описана ранее [16,17]. Зрелые ДК экспрессировали CD80, CD83, CD86, CCR7.…”

Section: материалы и методыunclassified

Personalized Immunotherapy in the Treatment of Patients with Malignant Gliomas

Рыков¹,

И.С.²,

Чкадуа³

2022

Гематология. Трансфузиология. Восточная Европа

View full text Add to dashboard Cite

Цель. Повышение выживаемости пациентов с глиомами. Материалы и методы. В исследование включены 5 пациентов в возрасте от 2 до 16 лет (средний возраст – 7,6 года). У трех пациентов диагностирована анапластическая астроцитома (AA), у одного пациента – мультиформная глиобластома (МГ) (3-й рецидив) и еще у одного пациента – диффузная глиома ствола мозга (ДГ). Среднее время до развития первого рецидива составило 12 месяцев (от 4 до 16 мес.), до развития второго – 5 месяцев (от 1 до 8 мес.). Протокол иммунотерапии включал комбинированное введение аутологичной вакцины на основе дендритных клеток (ДВ) и повторные интратекальные/внутрижелудочковые инъекции донорских аллогенных иммунокомпетентных клеток в течение не менее 2 лет. Результаты. У двух из трех пациентов с АА интервал без прогрессирования составил 67 и 71 месяц. Один пациент с третьим рецидивом МГ жив без какой-либо терапии через 13,3 года после начала иммунотерапии. Среднее время наблюдения составило 67 месяцев, общая двухлетняя выживаемость составила 58%. Два пациента умерли от прогрессирования заболевания в течение 6 и 7 месяцев от начала иммунотерапии. За период лечения пациенты получали в среднем 20 (от 8 до 60) инъекций аллогенных иммунокомпетентных клеток и 18 (от 8 до 44) инъекций ДВ. Побочных эффектов не наблюдалось. Заключение. Иммунотерапия может быть привлекательным вариантом для лечения пациентов со злокачественными глиомами высокой степени злокачественности, не поддающимися традиционной терапии, и заслуживает дальнейшего изучения. Purpose. Improving the survival rate of patients with gliomas. Materials and methods. Our study included 5 patients, median age 7.6 years (2–16). Three pts had anaplastic astrocytoma (AA) (1st recurrence – 1 pt, 2nd recurrence – 2 pts), 1 pt had glioblastoma multiforme (GBM) (3rd recurrence) and 1 pt had diffuse brainstem glioma (BSG). The median time to the first relapse was 12 months (4 to 16), to the second one – 5 months (1 to 8). The protocol of immunotherapy included combined administration of autologous dendritic cell-based vaccine (DV) and repeated intrathecal/intraventricular injections of donor allogenic immunocompetent cells (alloIC) for at least 2 years. Results. Two of 3 pts with AA experienced a progression-free interval of 67 and 71 months One pt. with 3rd GBM relapse is alive without any therapy 13.3 years after immunotherapy start. The median time of follow-up was 67 months with the 2-years overall survival was 58%. Two pts died from disease progression within 6 and 7 months from the start of immunotherapy. Over the period of treatment the pts received a median of 20 (8 to 60) alloIC injections and 18 (8 to 44) DV administrations. No serious side-effect was observed. Conclusion. Immunotherapy could be an attractive option for treating patients with high-grade malignant gliomas irresponsible to conventional therapy and is worthy of further investigation.

show abstract

Section: материалы и методыunclassified

Personalized Immunotherapy in the Treatment of Patients with Malignant Gliomas

Рыков¹,

И.С.²,

Чкадуа³

2022

Гематология. Трансфузиология. Восточная Европа

View full text Add to dashboard Cite

show abstract

Experience in the use of dendritic vaccines in the treatment of patients with recurrent gliomas

Rykov

Долгополов

2022

Issled. prakt. med. (Print)

View full text Add to dashboard Cite

Purpose of the study. To substantiate the expediency of cellular immunotherapy in the treatment of patients with relapses of high-grade gliomas and evaluate the safety of injecting allogeneic cells directly into the cerebrospinal fluid.Materials and methods. Our study included 5 patients, median age 7,6 years (2–16). Three patients had anaplastic astrocytoma (AA) (1st recurrence – 1 patient, 2nd recurrence – 2 patients), 1 patient had glioblastoma multiforme (GBM) (3rd recurrence) and 1 had diffuse brainstem glioma (BSG). The median time to the first relapse was 12 months (4 to 16), to the second one was 5 months (1 to 8). The protocol of immunotherapy included combined administration of autologous dendritic cell-based vaccine (DV) and repeated intrathecal/intraventricular injections of donor allogenic immunocompetent cells (alloIC) for at least 2 years.Results. Two of 3 patients with AA experienced a progression-free interval of 67 and 71 months One patient with 3rd GBM relapse is alive without any therapy 13.3 years after immunotherapy start. The median time of follow-up was 67 months with the 2‑years overall survival was 58 %. Two patients died from disease progression within 6 and 7 months from the start of immunotherapy. Over the period of treatment the patients received a median of 20 (8 to 60) alloIC injections and 18 (8 to 44) DV administrations. No serious side-effect was observed.Conclusion. Immunotherapy could be an attractive option for treating patients with high-grade malignant gliomas irresponsible to conventional therapy and is worthy of further investigation.

show abstract

Immunotherapy for children with malignant brain tumors

Dolgopolov,

Rykov

2024

Russian Journal of Immunology

View full text Add to dashboard Cite

The incidence of high-grade malignant gliomas (MG) ranges from 35 to 46% of all central nervous system tumors. Despite combined therapy including surgery, radiation treatment and chemotherapy, overall five-year survival does not exceed 10%. The advent of novel immunotherapeutic strategies has promoted a renewed hopes for the treatment of MG. The aim of the present study was to improve the survival rates of glioma patients. Our study included 5 pediatric patients at the median age of 7.6 years (2-16). Three pts had anaplastic astrocytoma (AA) (1st relapse, 1 pt; 2nd relapse, in 2 pts), One patient was diagnosed with glioblastoma multiforme (GBM) (3rd recurrence), and 1 child had diffuse brainstem glioma (BSG). The median time to the first relapse was 12 months (4 to 16), the second relapse occurred at a median of 5 months (1 to 8). The protocol of immunotherapy included combined administration of autologous dendritic cell-based vaccine (DV) and repeated intrathecal/intraventricular injections of donor allogeneic immunocompetent cells (alloIC) for at least 2 years. Two of 3 pts with AA experienced a progression-free interval of 67 and 71 months. One patient with 3rd GBM relapse is alive without any treatment for 13.3 years after starting the immunotherapy. The median time of follow-up was 67 months, with the 2-year overall survival rate of 58%. Two pts died from the disease progression within 6 and 7 months from the beginning of immunotherapy. Over the period of treatment, the patients received a median of 20 alloIC injections (8 to 60), and 18 DV administrations (8 to 44). No serious side-effects were observed. Immunotherapy could be an promising option for treating patients with high-grade malignant gliomas refractory to conventional therapy and, therefore, deserves further investigations.

show abstract

Cryo Preservation of Human Dendritic Cells for Clinical Use

Cited by 3 publications

References 7 publications

Personalized Immunotherapy in the Treatment of Patients with Malignant Gliomas

Personalized Immunotherapy in the Treatment of Patients with Malignant Gliomas

Experience in the use of dendritic vaccines in the treatment of patients with recurrent gliomas

Immunotherapy for children with malignant brain tumors

Contact Info

Product

Resources

About